Scope and claims of US Patent 11,534,433 and the US vulvovaginal candidiasis (VVC) patent landscape
US Patent 11,534,433 is directed to therapeutic and prophylactic dosing methods for VVC using a specific stereochemically defined compound of Formula (IIa) (and pharmaceutically acceptable salts/hydrates, with dependent emphasis on the citrate salt). The claims are anchored on three main constraints: (i) the exact compound identity (Formula IIa), (ii) VVC occurring at vaginal/anatomic pH < ~5, and (iii) total daily dose 150 to 600 mg, including sub-ranges (300 to 600 mg) and BID-like dosing constructs. Dependent claims narrow to oral administration and tablet dosing, and separate into treating vs preventing VVC, with a specific dependent callout for recurrent VVC.
What is US 11,534,433 claiming: treating vs preventing VVC with Formula (IIa) at pH < 5?
Claim 1: method of treating VVC at acidic pH with a fixed compound and dose band
Independent claim 1 sets the core legal scope:
- Use: “method of treating vulvovaginal candidiasis (VVC) infection in a subject”
- Active: administering a compound of Formula (IIa)
(stereochemical descriptor in the claim body)
plus “a pharmaceutically acceptable salt or hydrate thereof”
- Dose: total daily dose 150 to 600 mg
- Biological/clinical condition constraint: VVC occurs in a condition/anatomic area where pH is lower than about 5
This claim makes infringement dependent on proving all elements:
- the compound matches the Formula (IIa) stereochemical structure,
- dosing falls within 150–600 mg/day,
- the clinical scenario qualifies as VVC at pH < 5.
Dependent claims 2–5: tightening dose ranges and specified daily doses
- Claim 2: 300 to 600 mg/day
- Claim 3: BID dosing pattern with 150 to 300 mg per dose, totaling 300 to 600 mg/day
- Claim 4: administration at exact daily dose options: 150 mg, 300 mg, or 600 mg
- Claim 5: administration at 600 mg/day
These dependent claims create “laddered” infringing fallbacks. Even if an accused product uses a different daily dose within 150–600 mg/day, there are multiple claim hooks that could still read.
Claim 6: citrate salt specific narrowing
- Claim 6: “wherein the citrate salt of the compound of Formula (IIa) is administered”
This materially affects design-around risk. If an accused party uses another acceptable salt, claim 6 may not read, but claim 1 still may, because claim 1 covers “pharmaceutically acceptable salt or hydrate thereof” generally.
Claim 7–8: oral tablet constraint
- Claim 7: administered orally
- Claim 8: administered orally in a tablet
This supports narrower enforcement strategies for product formats (tablet formulations vs capsules/liquids) while still leaving broader scope in claim 1 (which does not require oral/tablet).
What independent claim covers prevention of VVC: is it a method-of-use “at pH < 5” plus 150–600 mg/day?
Claim 10: method of preventing VVC under the same compound and dosing constraints
Independent claim 10 mirrors claim 1 but switches the purpose:
- Preventing VVC infection
- Same Formula (IIa) compound (or salt/hydrate)
- Same total daily dose 150 to 600 mg
- Same pH < ~5 condition limitation
This claim enlarges the enforcement target beyond acute treatment. It also means a prophylaxis regimen could infringe even if it does not claim treatment of an active infection.
Claim 11: citrate salt narrowing
- Claim 11: citrate salt administered
Claim 12: oral route
- Claim 12: oral administration
Claim 13: recurrent VVC dependent
- Claim 13: VVC is recurrent VVC infection
This provides a specific clinical subgroup for enforcement, potentially aligning with payer/provider treatment protocols.
How are the citrate salt claims scoped: what is claimed when only the citrate salt is used?
Claim 14–15: oral administration of the citrate salt of Formula (IIa)
These claims are a second treatment track where the active is not merely “a salt,” but specifically the citrate salt.
- Claim 14 (independent within the excerpt):
“orally administering to the subject a citrate salt of a compound of Formula (IIa)”
with total daily dose 150 to 600 mg
- Claim 15 (dependent): citrate salt administered orally in a tablet
Practical scope impact: Claim 14 and 15 read only on citrate salt users. They add product-format and salt identity certainty for infringement arguments and can capture marketing/regulatory label directions that call out citrate.
What does the pH < about 5 limitation do to claim scope and infringement risk?
Claim-structure implications
The phrase “wherein the VVC infection occurs in a condition or an anatomic area in which the pH is lower than about 5” is a biological condition limitation. For infringement, the patentee’s theory typically depends on:
- how vaginal pH is measured or clinically characterized in the patient population, and
- whether the accused regimen is used in practice for the claimed VVC setting.
From a freedom-to-operate angle, the limitation can be both a constraint and a litigation lever:
- It narrows the covered use case compared to “any VVC regardless of pH.”
- It also provides a factual inquiry point in litigation: patient pH at diagnosis or during occurrence.
“Treating” vs “preventing” with the same pH element
Because both treatment and prevention independent claims include the pH < 5 limitation, prophylaxis regimens are still tied to a clinical microenvironment that qualifies as acidic under about-5 criteria.
What does the dose band (150–600 mg/day) mean for generic or competitor entry?
Dose band coverage
The independent claims cover all total daily doses between 150 and 600 mg, inclusive as drafted. Dependent claims carve out:
- 300–600 mg/day (claim 2)
- BID with 150–300 mg per dose and total 300–600 mg/day (claim 3)
- exact totals: 150, 300, 600 mg (claim 4)
- 600 mg/day (claim 5)
Common design-around levers created by the claim language
- Outside dose band: A regimen below 150 mg/day or above 600 mg/day could avoid the literal dose limitation, subject to doctrine-of-equivalents analysis.
- Avoid pH < 5 scenario: Less feasible in practice because VVC and vaginal microenvironments are patient-dependent, and claim ties to “occurs in a condition/anatomic area.”
- Avoid the compound identity: Only variants not covered by Formula IIa would avoid claim reading, but that requires changing the molecule, not just the route or salt (unless the salt is relied upon for a dependent claim).
Which route and dosage forms are protected: oral, tablet, and general salt/hydrate coverage
Route specificity by dependency
- Independent claims (1, 10) do not require oral or tablet; they require compound identity, dose band, and pH < 5.
- Oral administration is in dependent claims (7, 12).
- Tablet format is in dependent claims (8, 15).
This matters because a product in non-tablet oral forms (e.g., capsules, sachets) still may infringe claim 1 or 10 if other elements are met, but claims 8 or 15 would require the tablet format.
Salt scope
- Independent claims cover “pharmaceutically acceptable salt or hydrate thereof.”
- Dependent claims focus on citrate.
So the salt identity is important mainly for dependent-claim strategies, not the broadest claim.
What formulations are protected by this claim set?
Covered formulation attributes (from the excerpted claims)
Within the provided claim language, the protected “formulation” aspects are limited to:
- salt identity: citrate singled out in claims 6, 11, 14, 15
- dosage form: tablet singled out in claims 8 and 15
- route: oral singled out in claims 7, 12, 14, 15
The excerpt does not specify excipients, solid-state form, polymorphs, particle size, controlled release profiles, or manufacturing parameters. Those may exist in other claims or related patents, but they are not present in the text provided.
Patent landscape positioning: what claims like these typically mean for enforcement strategy in VVC
Typical enforcement posture
Claims limited to:
- a single defined chemical entity (Formula IIa),
- a clinical context (VVC at vaginal/anatomic pH < 5),
- and a dose band
are designed to be enforceable against:
- the branded product during label-consistent use,
- generics that replicate the same dosing regimen and are used in the same patient environment,
- prophylaxis labeling or off-label practice aligned with “preventing VVC infection” under pH < 5.
How this differs from broader VVC therapeutic claims
Many VVC patent estates cover:
- any azole use,
- combinations,
- or broader pH-independent methods.
This estate, as reflected in the excerpt, is tighter because it requires the pH condition and the Formula IIa compound.
What is the practical scope of claim coverage if an accused regimen uses a different salt than citrate?
- If an accused product uses a pharmaceutically acceptable salt other than citrate, it can still fall within claim 1 (treating) or claim 10 (preventing) because those cover “salt or hydrate thereof” generally.
- It avoids dependent claims 6, 11, 14, and 15, which require citrate specifically.
So the carve-out is partial: avoiding citrate-dependent claims does not necessarily eliminate infringement exposure.
What is the commercial and regulatory exposure implied by claim 1/10 dosing and method-of-use elements?
Label directions and real-world dosing
In practice, the most common infringement pathway is when:
- an FDA label or standard clinical protocol specifies a dosing regimen within 150–600 mg/day and is used in a VVC context where vaginal pH is acidic (often <5 in many microenvironments, depending on patient and assay).
- a prophylaxis regimen is marketed or prescribed consistent with “preventing VVC infection” plus the pH < 5 clinical qualifier.
Because the claims are method-of-use, regulatory exclusivity (NDA/505(b)(1) vs ANDA) is less central to infringement than real-world use. But the company that files for approval and controls labeling can still influence how easily the pH and dosing elements are proven in court.
Key Takeaways
- US 11,534,433 claims method-of-use treatment and prevention of vulvovaginal candidiasis using a specific stereochemically defined Formula (IIa) compound (and acceptable salts/hydrates).
- The scope is defined by three core limitations: (i) compound identity, (ii) total daily dose 150–600 mg, and (iii) VVC occurs in a condition/anatomic area with pH lower than about 5.
- Dependent claims create enforcement lanes by narrowing to dose subranges, BID dosing, exact daily doses, citrate salt, and oral tablet format, plus recurrent VVC.
- A competitor using a non-citrate salt may avoid citrate-dependent claims but can still infringe broader independent claims if the dose and pH elements and compound identity are met.
FAQs
-
Does US 11,534,433 require that vaginal pH be measured by a specific method?
The claim text requires pH < about 5 in the condition/anatomic area; it does not specify a test method in the provided claim language.
-
Can infringement occur if the accused product uses a pharmaceutically acceptable salt other than citrate?
Yes for broader independent claims because they cover “a pharmaceutically acceptable salt or hydrate thereof,” while citrate is required only in dependent claims.
-
Is tablet dosing mandatory to infringe?
No. Tablet is only required in dependent claims. Independent claims cover non-tablet dosing if route requirements are satisfied in the practice context.
-
Does the patent cover prophylaxis for recurrent VVC specifically?
Dependent claim 13 calls out “recurrent VVC infection,” but independent claim 10 covers prevention more generally.
-
What is the main easiest design-around concept suggested by the claim language?
Avoiding the 150–600 mg/day total daily dose band is the clearest textual lever; salt and formulation changes primarily affect dependent-claim coverage.
References
- US Patent 11,534,433, “Method of treating or preventing vulvovaginal candidiasis,” claims as provided in user excerpt.
